Latest updates & what is forthcoming

February 9, 2021

Here's what to look out for --

Previews of unpublished data undergoing peer review:

• drug prophylaxis for COVID-19 (including hydroxychloroquine and ivermectin)

  • anticipated by mid-February

• antibodies and cellular therapies for treatment of COVID-19 (including convalescent plasma and bamlanivimab)

  • ​anticipated by mid-February

• updated data on drug treatments for COVID-19

  • anticipated by early March​

Peer-reviewed versions of the following:

• adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir

​

We're also studying the credibility of trial preprints during the COVID-19 pandemic. Stay tuned for our study protocol!

​

Send us a message here if you have any questions about what is forthcoming!

​